GET DAILY SIGNALSCoherus BioSciences (CHRS) Stock Plunges -51% in 30 Days on Earnings Concerns
Key Takeaways
- Coherus BioSciences shares fell roughly 51% over the last 30 days, sliding from about $1.05 to near $0.52.
- The decline accelerated after third-quarter 2026 results that missed revenue estimates and included a cut to full-year LOQTORZI guidance.
- Management announced an approximately 30% workforce reduction and disclosed a going-concern warning with less than 12 months of cash runway.
- LOQTORZI revenue reached $14.0 million in the third quarter, up 25% year over year, but sequential growth of just 3% missed the company's own 10%–15% target.
- A promising esophageal cancer signal for tagmokitug was overshadowed by balance-sheet and financing concerns.
- Over the last quarter, the stock has fallen roughly 55%, from about $1.15 in mid-August.
Coherus BioSciences (CHRS) Background and Current Focus
Coherus BioSciences, Inc., now operating as Coherus Oncology, is a commercial-stage biopharmaceutical company centered on oncology. Its lead product, LOQTORZI (toripalimab-tpzi), is an anti-PD-1 antibody approved by the FDA for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma. The company has shifted from its earlier biosimilars operations, including UDENYCA, by divesting that franchise to concentrate on its cancer pipeline. The main clinical candidate remains tagmokitug, an antibody aimed at depleting regulatory T cells and currently being studied in combination with toripalimab, with efforts now focused on esophageal cancer. I find CHRS worth following because its prospects depend heavily on LOQTORZI’s commercial progress and the ability to secure financing for ongoing programs.
CHRS Stock Performance Over the Past 30 Days and Quarter
In the last 30 days, CHRS shares dropped about 51%, moving from a mid-October close near $1.05 down to roughly $0.52 by mid-November. Much of the selling occurred right after the third-quarter earnings report as financing and going-concern issues took center stage.
The quarterly picture looks even steeper. From around $1.15 in mid-August, the stock has declined roughly 55% through mid-November. This reflects a steady, multi-month pullback rather than a one-day reaction, as investor confidence in the company’s path to financial stability continued to fade.
What Pushed the Stock Lower in the Last 30 Days
The recent drop stemmed mainly from the third-quarter 2026 results and related announcements. Coherus reported net revenue of $14.27 million, below the consensus estimate near $15.9 million, while LOQTORZI net sales came in at $14.0 million. Sequential growth of just 3% fell short of the 10%–15% pace previously targeted.
More significant was the reset in expectations. The company lowered full-year 2026 LOQTORZI guidance to $54 million–$57 million from $57 million–$62 million, disclosed an approximately 30% workforce reduction, and narrowed its pipeline emphasis to esophageal cancer. It also included a going-concern warning, noting less than 12 months of cash runway without additional measures. Cash and investments stood at $83.6 million at quarter-end, down from $105.3 million three months earlier. These points raised dilution and financing worries that overshadowed positive esophageal cancer data for tagmokitug and drove the sell-off. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Broader Pressures Behind the Quarterly Decline
The three-month slide reflects a company whose spending still exceeds the revenue generated by its marketed product. Coherus has been transitioning to a focused oncology player, yet LOQTORZI uptake has lagged what is needed to cover operating costs. With quarterly sales near $14 million and ongoing losses in the tens of millions, cash reserves have declined steadily. Across the period, investors adjusted their view as earlier assurances about funding through clinical milestones gave way to the going-concern disclosure. A term-loan refinance added only about $11.5 million in net cash, and a UDENYCA earn-out milestone was missed, leaving greater reliance on cost reductions and potential partnerships.
Key Developments to Watch for CHRS Investors
Several items will influence CHRS shares ahead. The FDA action date for the drug-product portion of the toripalimab manufacturing transfer application is set for November 30. The company also intends to discuss a development path for tagmokitug in second-line esophageal cancer, where an expedited-approval route could serve as a catalyst. Ex-U.S. partnering talks for tagmokitug may deliver upfront payments, while the disputed UDENYCA earn-out remains unresolved. LOQTORZI’s fourth-quarter trajectory, guided around $15 million, and the company’s success in raising additional capital without heavy dilution will matter most to sentiment. These remain factual points to monitor.
How Tickeron AI Tools Support My Research
I occasionally turn to Tickeron’s AI Trading Bots when evaluating how automated strategies are positioned around volatile names like CHRS. The platform offers a range of bots with different timeframes and approaches, which helps me cross-check sentiment and potential patterns without replacing my own fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CHRS's RSI Oscillator dives oversold zone
The RSI Oscillator for CHRS moved into overbought territory on November 11, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.498). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement